Novartis’ treatment of multiple myeloma was granted orphan designation by the FDA, according to a post to the agency’s website. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NVS:
- Avrobio exploring potential sale after approach, Street Insider says
- Immix Biopharma doses first two patients in Phase 1b/2a combination trial
- Novartis’ Sandoz BLA for proposed biosimilar denosumab accepted by FDA
- Novartis (NYSE:NVS) Down on Sluggish Q4 Sales
- Novartis sees core operating income to grow mid single digit percentage in 2023